DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.
Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:
- Royalty-free to ensure the lowest possible price
- Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
- Worldwide coverage both for R&D and for manufacture
- Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)
An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.
Pharmaceuticals
AbbVie (USA) Projects: Screening / Lead optimization / Leish H2L / Chagas H2L / AbbV4083 (Tylamac) / Two ‘4-in-1’ LPV/r based FDC granules
Astellas Pharma (Japan) Projects: Screening
AstraZeneca (UK) Projects: Screening / Discovery / Lead optimization/ Leish H2L
Avista Pharma (formerly SCYNEXIS) (USA) Projects: SCYX-7158
Bayer Healthcare (Germany) Projects: Emodepside
Bristol-Myers Squibb (USA) Projects: Screening
Cipla Inc. (India) Projects: Two ‘4-in-1’ LPV/r based FDC granules / LPV/r pellets with dual NRTI FDC / ASMQ
Daiichi Sankyo (Japan) Projects: Screening
Debiopharm (Switzerland) Projects: Discovery
Eisai Co., Ltd. (Japan) Projects: Screening / Discovery / Fosravuconazole / New benznidazole regimens
E.I du Pont Nemours (USA) Projects: Screening
Farmanguinhos (Fiocruz) (Brazil). Projects: ASMQ
GeneDesign Inc. (Japan) Projects: CpG-D35
Gilead Sciences (USA) Projects: Fexinidazole
GlaxoSmithKline (Spain) Projects: Screening / Lead optimization / Leish H2L
GNF Novartis, Genomics Institute of the Novartis Research Foundation (USA). Projects: Screening
Humax Pharmaceutical (Colombia) – Projects: Anfoleish
Janssen (Belgium) – Projects: Screening
LAFEPE (Brazil) Projects: Paediatric dosage form of benznidazole
Mercachem (The Netherlands) Projects: Screening
Merck (USA) – Projects: Screening / Lead optimization / Leish H2L
Merck Serono (Germany) Projects: Screening
Optimed (France) Projects: Fexinidazole-Miltefosine combination
Paladin Labs (Canada) Projects: New VL treatments – Africa
Pharco Pharmaceuticals Inc. (Egypt) Projects: Sofosbuvir/Ravidasvir
Pfizer Ltd. (UK) – Projects: Screening / Lead optimization/ Aminopyrazoles
Sanofi (France) Projects: Screening / Lead optimization/ Leish H2L / Chagas H2L / Fexinidazole
Sanofi and affiliates (France) Projects: ASAQ / Fexinidazole / Screening
Sanofi-Chinoin (Hungary) Projects: Fexinidazole-Miltefosine combination
Sara Pharm (Romania) Projects: DNDi-6148
Shionogi (Japan) Projects: Discovery
Syngene (India) Projects: DNDi-6148
Takeda Pharmaceutical Company Ltd. (Japan) Projects: Screening / Discovery / Aminopyrazoles
Zenufa Laboratories Ltd (Tanzania) Projects: ASAQ
Biotechs
Anacor Pharmaceuticals (USA) Projects: Screening / Lead optimization / SCYX-1330682 SCYX-1608210 / Leish H2L / DNDi-5421 DNDi-5610 / SCYX-7158 / DNDi-6148
Celgene (USA) Projects: Screening / Discovery / Lead optimization
Celgene Global Health (USA) Projects: CGH VL series 1
Evolva (Switzerland) Projects: Discovery
Genzyme (USA) Projects: Material transfer for research and development on HAT, Chagas disease, and leishmaniasis.
iThemba Labs (South Africa) Projects: Lead optimization
Polytherics (UK) Projects: Formulation of amphotericin B, in collaboration with Imperial College.
SCYNEXIS Inc. (USA) Projects: Lead optimization / SCYX-1330682 SCYX-1608210 / SCYX-7158
Sequella, Inc. (USA) Projects: Screening
Vertex (USA) Projects: Screening
Universities
Addis Ababa University (Ethiopia) Projects: New treatments for HIV/VL co-infection / SSG&PM
Antwerp University (Belgium) Projects: Screening / Lead optimization/ SCYX-1330682 SCYX-1608210
Auckland University (New Zealand) Projects: DNDi-0690 / Lead optimization
Banaras Hindu University, Institute of Medical Sciences (India) Projects: / New treatments for PKDL
Baylor College of Medicine Children’s Foundation (Uganda) Projects: LPV/r pellets with dual NRTI FDC
Bonn University Hospital, Institute of Medical Microbiology, Immunology and Parasitology (Germany) Projects: Screening
Brasilia University (Brazil) Projects: New VL treatments Latin America
Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de Clermont-Ferrand (France) Projects: Fexinidazole-Miltefosine combination
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
Federal University of Sergpipe (Brazil) Projects: New VL treatments Latin America
Fundacao de Apoio Universidade Federale de Sao Paolo (FapUnifesp) (Brazil) Projects: Lead optimization / Leish H2L / Chagas H2L
Fundação de Apoio Universidade Federalede Sao Paolo (Brazil) Projects: Lead optimization
Gondar University Hospital (Ethiopia) Projects: New treatments for HIV/VL co-infection / SSG&PM
Imperial College (UK) Projects: Formulation of amphotericin B with Polytherics.
Khartoum University, Institute of Endemic Disease (Sudan) Projects: Fexinidazole-Miltefosine combination / new treatments for PKDL / SSG&PM / Fosravuconazole
London School of Hygiene and Tropical Medicine (UK) Projects: Screening / Lead optimization/ Aminopyrazoles / DNDi-5421 DNDi-5610 / VGH VL series 1 / Chagas H2L / Biomarkers / Leish H2L / DNDi-6148 / DNDi-0690 / Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / SSG&PM / New VL treatments Asia
London School of Pharmacy (UK) Projects: Formulation of amphotericin B, in collaboration with Imperial College.
Makarere University (Uganda) Projects: Fexinidazole-Miltefosine combination / SSG&PM / MF/PM combination therapy
McGill University (Canada) Projects: Biomarkers
Michigan State University (USA) Projects: Flubendazole Macrofilaricide (Filarial diseases)
Monash University, Centre for Drug Candidate Optimization (Australia) Projects: Lead optimization/ Chagas H2L / Leish H2L
Murdoch University, School of Veterinary and Biomedical Science (Australia) Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization
Montes Claros State University (Brazil) Projects: New VL treatments Latin America
Nagasaki University (Japan) Projects: CpG-D35
Ohio State University (USA) Projects: CpG-D35
Pace University (USA) Projects: SCYX-1330682 SCYX-1608210
Perinatal HIV Research Unit, University of Witswatersrand (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
Piaui Federal University (Brazil) Projects: New VL treatments Latin America
Radboud University Medical Center (The Netherlands) Projects: Fosravuconazole
Stellenbosch University (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
Universidad Autónoma Juan Misael Saracho (Bolivia) Projects: Biomarkers / New benznidazole regimens / Fexinidazole
Universidad Autónoma Juan Misael Saracho (Spain) Projects: New benznidazole regimens / Fexinidazole
Universidade Estadual de Campinas UNICAMP (Brazil) Project: Lead Optimization
Universidad Mayor de San Simon (Bolivia) Projects: Biomarkers
Universidad Peruana Cayetano Heredia (Peru) Projects: New CL combination therapies
Universidad San Martin (Argentina) Projects: Biomarkers
Estadual do Rio de Janeiro (Brazil) Projects: New VL treatments Latin America
University de Antioquia, Programa de Estudio y Control de Enfermedades Tropiales (Colombia) Projects: Anfoleish / New CL combination therapies
University of Antwerp, Laboratory of Microbiology, Parasitology and Hygiene (Belgium) Projects: DNDi-5421 DNDi-5610 / Aminopyrazoles / Lead optimization/ Leish H2L / DNDi-6148 / DNDi-0690 /
University of Campinas, Brazilian Biosciences National Laboratory (Brazil) Projects: Lead optimization/ Chagas H2L
University of Dundee, Drug Discovery Unit (UK) Projects: Screening
University of Nairobi (Kenya) Projects: LPV/r pellets with dual NRTI FDC
University of Osaka (Japan) Projects: CpG-D35
University of Texas at El Paso (USA) Project: Biomarkers
Uppsala University (Sweden) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / new treatments for PKDL
Utrecht University (The Netherlands) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection / MF/PM combination therapy
Various academic partners (South Africa and Kenya) Projects: Two ‘4-in-1’ LPV/r based FDC granules
UCSF, University of California, San Francisco (USA) Projects: K777 (Chagas) / RTV Superbooster for HIV/TB co-infection (Paediatric HIV)
University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.
Universidade Ouro Preto (Brazil) Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization
University of Oxford, Worldwide Antimalarial Drug Resistance Network (UK) Projects: ASAQ (Malaria) / ASMQ (Malaria)
University Sains (Malaysia) Projects: ASAQ (Malaria) / ASMQ (Malaria)
University “Spin-off”
Epichem (Australia) Projects: Screening / Leish H2L /Chagas H2L / Lead optimization
Eskitis Institute for Cell and Molecular Therapies, Griffith University (Australia) Projects: Lead optimization/ Chagas H2L / Leish H2L
Research Institutes
Administración Nacional de Laboratorios e Institutos de Salud (Argentina) Projects: Paediatric dosage form of benznidazole
Broad Institute, MIT and Harvard (USA) Projects: Discovery activity for Chagas disease
CRESIB, Centre de Recerca en Salut Internacional de Barcelona (Spain). Since September 2010, DNDi partner for the clinical phase for Chagas disease. Projects: Azoles E1224 & Biomarker (Chagas)
Dr Mario Fatala Chaben National Institute of Parasitology (Argentina) – Projects: Biomarkers
FIPEC: Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (Argentina) Projects: Clinical studies for Chagas disease.
Georges Institute for International Health (Australia) Projects: ASAQ
Institut de Recherche pour le Développement (France) Projects: SCYX-7158 / Fexinidazole
Institut National de Recherche Biomédicale (DRC) Projects: SCYX-7158 / Fexinidazole
Institute of Tropical Medicine Antwerp (Belgium) Projects: SCYX-7158 / Fexinidazole / New treatments for HIV/VL co-infection / New VL treatments Asia
Instituto Nacional de Epidemiología Dr Fatala Cháben (Argentina) Projects: New benznidazole regimens / Paediatric dosage form of benznidazole
IMEA Consulting France: Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France) Projects: ASAQ
IEND, Institute of Endemic Disease, Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP) Projects: Fexinidazole (VL) / VL-0208 / SSG&PM (VL in Africa)
Ifakara Health Institute (Tanzania) Projects: ASMQ (Malaria)
IRD, Institut de Recherche pour le Développement (France) Projects: ASAQ (Malaria)
Institut Pasteur (France) Projects: Screening
Institute of Tropical Medicine (Belgium) Projects: VL-0208 / HIV/VL
Kenya Medical Research Institute (Kenya) Projects: Fexinidazole-Miltefosine combination / MF/Paromomycin combination therapy / LPV/r pellets with dual NRTI FDC / SSG&PM
Kononklijk Instituut voor de Tropen (The Netherlands) Projects: Fexinidazole-Miltefosine combination
Medical Research Council (UK) Projects: Two 4-in-1 LPV/r-based fixed-dose combinations (Paediatric HIV)
National Institutes of Health (USA) Projects: Screening / CpG-D35
Necker Institute (France) Projects: Two ‘4-in-1’ LPV/r based FDC granules
Northwick Park Institute for Medical Research (UK) Projects: Screening
Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) (India) Projects: New treatments for PKDL / New VL treatments Asia
Shandukani Research Centre Wits Reproductive Health and HIV Institute (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
The Institut Pasteur (South Korea) Projects: Screening
The Netherlands Cancer Institute (The Netherlands) Projects: Fexinidazole-Miltefosine combination / New treatments for HIV/VL co-infection
The Swiss Tropical and Public Health Institute (Switzerland) Projects: Screening / SCYX-7158 / Fexinidazole / NECT / SSG&PM
University of Georgia Research Foundation (USA) Projects: Biomarkers
Walter Reed Army Institute (USA) Projects: Screening
National Research Centres
Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) (Argentina) Projects: Clinical trials for Chagas disease.
Barcelona Centre for International Health Research (Spain) Projects: Biomarkers
B.P Koirala Institute of Health Sciences (Nepal) Projects: Clinical trials for visceral leishmaniasis.
CNRFP, Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso) Projects: ASMQ (Malaria)
CDRI, Central Drug Research Institute (India) Projects: VL-2098 / Nitroimidazole backup (VL)
CSIR, Council of Scientific and Industrial Research (India) Projects: Various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.
Erasmus Medical Centre (The Netherlands) Projects: Fosravuconazole
Fiocruz, Fundaçao Oswaldo Cruz (Brazil) Projects: Azoles E1224 & Biomarker (Chagas)
Indian Council of Medical Research (ICMR) (India) Projects: New VL treatments Asia
International Centre for Diarrhoeal Disease Research (Bangladesh) Projects: New treatments for PKDL / New VL treatments Asia
IS Global, Centre de Recerca en Salut Internacional de Barcelona (Spain) Projects: New benznidazole regimens/ fexinidazole
Joint Clinical Research Centre (Uganda) Projects: LPV/r pellets with dual NRTI FDC
Kala Azar Medical Research Centre (India) Projects: New treatments for PKDL / New VL treatments Asia
LNBio/CNPEM (Brazil) Projects: Lead optimization
Medical Research Council (UK) Projects: Two ‘4-in-1’ LPV/r based FDC granules
Mycetoma Research Centre, Soba University Hospital (Sudan) Projects: Fosravuconazole
National Institute for Medical Research (NIMR) (Tanzania) Projects: ASMQ (Malaria)
National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) Projects: Biomarkers
National Vector Borne Disease Control Programme (India) Projects: New VL treatments Asia
Northwick Park Institute for Medical Research (UK) Projects: Screening
Novartis Centre de la Recherche Santé Animale (Switzerland) Projects: Screening
Rene Rachou Research Center – Fiocruz MG (Brazil) Projects: New VL treatments Asia
Seattle Biomedical Research Institute (USA). Projects: Discovery for NTDs.
Texas Biomedical Research (USA) Projects: Biomarkers
NGOs/IOs
AEDES, consulting firm for Social and Public health sector (Belgium) Projects: ASAQ (Malaria)
Clinton Access Health Initiative (USA) Projects: LPV/r pellets with dual NRTI FDC
Collective of Applied Studies and Social Development (CEADES) (Bolivia) Projects: Azoles E1224 & Biomarker (Chagas)
Communauté Baptiste du Congo (Democratic Republic of Congo) Projects: Fexinidazole (HAT)
Epicentre (France) Projects: NECT
Epicentre Research Center (Uganda) Projects: LPV/r pellets with dual NRTI FDC
Fundación Mundo Sano and ELEA (Argentina) Projects: New benznidazole regimens / Paediatric dosage form of benznidazole
IDA Foundation (The Netherlands) Projects: VL-0208
i+solutions (The Netherlands) Projects: VL-0208 / SSG&PM (VL for Africa)
Médecins Sans Frontières Projects: ASAQ (Malaria) / Azoles E1224 & Biomarker (Chagas) / Fexinidazole (VL) / HIV/VL / NECT / NECT (HAT) / VL-0208 / New VL treatments (Asia) / SSG&PM (VL in Africa) / New treatments for HIV/VL co-infection / SSG&PM / Two ‘4-in-1’ LPV/r based FDC granules / Biomarkers / Fexinidazole (Chagas)
Microbial Chemistry Research Foundation (Japan) Projects: Screening
OTECI, Offre Technique d’Etude et de Coopération Internationale (France) Projects: ASMQ
Royal Society of Chemistry (UK): MoU to promote open source discovery.
UNITAID (Switzerland) Projects: Two ‘4-in-1’ LPV/r based FDC granules / Projects: LPV/r pellets with dual NRTI FDC
WHO-TDR: (Switzerland) Projects: ASAQ (Malaria) / ASMQ (Malaria) / New VL treatments (Asia) / Screening / New VL treatments Asia
PDPs/PPPs
FIND, Foundation for Innovative New Diagnostics (Switzerland) Projects: Collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. MoU for collaboration in the field of neglected tropical diseases.
Medicines for Malaria Venture (MMV) (Switzerland) Projects: Screening
Novartis Institute for Tropical Diseases (Singapore) Projects: Lead optimization
OWH, Institute for One World Health (USA) Projects: VL-0208 / New VL treatments (Asia) / SSG&PM (VL in Africa)
TB Alliance (USA) Projects: Nitroimidazole (Chagas) / SCYX-2035811 / VL-2098 / Screening and Lead Optimization / Lead optimization/ DNDi-0690
TI Pharma (The Netherlands) Projects: DNDi partner for discovery activities.
Hospitals
Amudat General Hospital (Uganda) Projects: Fexinidazole-Miltefosine combination / SSG&PM
Arba Minch Hospital (Ethiopia) Projects: SSG&PM
CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland) Projects: ASMQ (Malaria)
Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
Gertrude’s Children’s Hospital (Kenya) Projects: LPV/r pellets with dual NRTI FDC
Hospital de Niños de Jujuy (Argentina) Projects: Paediatric dosage form of benznidazole
Hospital de Niños Dr. Ricardo Gutiérrez (Argentina) Projects: Paediatric dosage form of benznidazole
Hospital General de Valencia (Spain) Projects: New benznidazole regimens
Hospital Independencia, Centro de Chagas y Patologia Regional (Argentina) Projects: Paediatric dosage form of benznidazole
Hospital Público Materno Infantil (Argentina) Projects: Paediatric dosage form of benznidazole
Hospital Sao José de Doencas Infecciosas (Brazil) Projects: New VL treatments Latin America
KATH, Komfo Anokye Teaching Hospital (Ghana) Projects: ASAQ (Malaria)
Makerere University (Uganda) Projects: SSG&PM
Mbagathi District Hospital (Kenya) Projects: LPV/r pellets with dual NRTI FDC
Moi Teaching and Referral Hospital (Kenya) Projects: LPV/r pellets with dual NRTI FDC
Muséum National d’Histoire Naturelle (France) Projects: Screening
Paediatric Hospital Joao Paulo II – FHEMIG (Brazil) Projects: New VL treatments Latin America
Shaheed Suhrawardy Medical College and Hospital (Bangladesh) Projects: New VL treatments Asia
St. Lumumba Health Centre (Kenya) Projects: LPV/r pellets with dual NRTI FDC
Tygerberg Children’s Hospital (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
University Hospitals of Geneva (Switzerland) Projects: Biomarkers
Ministries of Health/Governmental Organizations
Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP) Projects: Various partnerships for clinical trials in the field of leishmaniasis / New VL treatments (Africa) / SSG&PM (VL in Africa)
Bihar State Health Society (India) Projects: New VL treatments Asia
CDC/President’s Emergency Plan for AIDS Relief (USA) Projects: Two ‘4-in-1’ LPV/r based FDC granules
CeNDIE, Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias, Ministry of Health, (Argentina) Projects: Paediatric Benznidazole (Chagas)
Clinical Research Malaysia, Ministry of Health (Malaysia) Projects: Sofosbuvir/Ravidasvir
Department of Health and Department of Science and Technology (South Africa) Projects: Superbooster therapy for HIV/TB co-infection
Department of Health South Africa (South Africa) Projects: Two ‘4-in-1’ LPV/r based FDC granules / LPV/r pellets with dual NRTI FDC
Leishmaniasis Control Programme/ Ministry of Health (Brazil) Projects: New VL treatments Latin America
Ministry of Health (Brazil) Projects: New VL treatments (Latin America)
Ministry of Health (Cambodia) Projects: ASMQ (Malaria)
Ministry of Health (Rep. Dem. Congo) Projects: Various partnerships (financial and clinical trial agreement) in the field of HAT.
Ministry of Public Health (DRC) Projects: NECT
Ministry of Health (Ethiopia) Projects: SSG&PM
Ministry of Health (Kenya) Projects: LPV/r pellets with dual NRTI FDC / SSG&PM / VL-0208
Ministry of Health (Sudan) Projects: New treatments for PKDL / SSG&PM
Ministry of Health (Uganda) Projects: SSG&PM / VL-0208
Ministry of Health and Family Welfare (Bangladesh) Projects: New VL treatments Asia
Ministry of Health, Province of Jujuy (Argentina) Projects: Paediatric dosage form of benznidazole
National Trypanosomiasis Control Programme (DRC) Projects: NECT
Contract Research Organizations (CROs)
Accelera (Italy) – Projects: DNDi-0690
Advinus Therapeutics Ltd. (India) – Projects: SCYX-7158
Aptuit (Italy) – Projects: DNDi-0690 / Fexinidazole-Miltefosine combination
BaseCon (Denmark) Projects: Fexinidazole-Miltefosine combination / New treatments for – HIV/VL co-infection
Bertin Pharma (France) Projects: ASAQ (Malaria) / VL-2098 / Oxaborole SCYX-7158 (HAT) / Fexinidazole (HAT)
Cardiabase (France) Projects: Fexinidazole-Miltefosine combination
Calvert Labs (USA) Projects: Pre-clinical phase for topical formulation against cutaneous leishmaniasis.
Cardinal System (France) Projects: Azoles E1224 & Biomarker (Chagas)
Catalent (USA) Projects: Screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.
Centipharm (France) Projects: CMC/manufacture of fexinidazole for HAT.
Central Diagnostics (India) Projects: Partner in the field of visceral leishmaniasis.
Clinwin Research Services (Kenya) Projects: ASMQ (Malaria)
CoreLab Partners (USA) Projects: Clinical activity for Chagas disease.
Covance (UK) Projects: VL-2098
Creapharm (France) Projects: Fexinidazole (Chagas)
Drugabilis (France) Projects: Screening & Lead Optimization / Fexinidazole (HAT) / Oxaborole SCYX-7158 (HAT) / Flubendazole (Filarial diseases) / VL-2098
Endolytics (USA) Projects: VL-2098
Eurofins Optimed (France) Projects: Oxaborole SCYX-7158 (HAT) / Two “4-in-1” LPV/r based FDC granules (Paediatric HIV)
Frontage (USA) Projects: Azoles E1224 & Biomarker (Chagas)
GVK Biosciences (India) Projects: Clinical phase for malaria and VL.
Harlan Laboratories (Switzerland) Projects: Pre-clinical research agreement for Chagas disease.
Huntingdon Life Sciences Limited (UK) Projects: VL-2098
JSS Medical Research (Canada) Projects: Anfoleish (CL) / Fexinidazole (Chagas)
LAT Research (Argentina) Projects: Azoles E1224 & Biomarker (Chagas)
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres” (INGEBI-CONICET) (Argentina) Projects: New benznidazole regimens /Fexinidazole
National Council of Scientific and Technological Research (INGEBI-CONICET) (Argentina) Projects: Azoles E1224 & Biomarker (Chagas) / Paediatric Benznidazole (Chagas)
Nucleo de desenvolvimento farmacêutico e cosméticos (NUDFAC) (Brazil) Projects: Azoles E1224 & Biomarker (Chagas) / Paediatric Benznidazole (Chagas)
Patheon (UK) Projects: Formulation development and manufacturing for HAT.
Penn Pharmaceuticals Services (UK) Projects: Oxaborole SCYX-7158 (HAT)
PhinC (France) – Projects: Fexinidazole-Miltefosine combination
RCTs (France) Projects: NECT (HAT) / Fexinidazole (HAT)
Roowin (France) Projects: CMC activities for HAT.
Sandexis (UK) Projects: Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148
Sigma-Aldrich (UK) Projects: VL-2098
SGS (France). Projects: Clinical study of fexinidazole for HAT, subsequently performing bioanalyses.
SGS (Belgium) Projects: Fexinidazole-Miltefosine combination
Theradis Pharma (France) Projects: Fexinidazole (HAT)
WuXi AppTech (China) Projects: Screening/ Lead optimization/ Leish H2L / DNDi-5421 DNDi-5610 / Aminopyrazoles / CGH VL series 1 / Chagas H2L / DNDi-6148 / DNDi-0690 / Two ‘4-in-1’ LPV/r based FDC granules
Platforms and Networks
HAT Platform Projects: NECT
Leishmaniasis East Africa Platform Projects: Fexinidazole-Miltefosine combination / New treatments for PKDL / New treatments for HIV/VL coinfection / SSG&PM
National Control Programmes of the DRC and CAR Projects: Fexinidazole
NHEPACHA Network Projects: Biomarkers
Platform of Integral Care for Patients with Chagas Disease (Bolivia) Projects: New benznidazole regimens/ Fexinidazole
Please contact us at partnership@dndi.org to propose collaborative projects.